ライフサイエンスコーパス: Guerin

1 Guerin et al. (2014) report the first direct experimenta

2 vation of the M. bovis bacillus Calmette and Guerin (BCG) vaccine strain selected for an M. bovis PK+

3 augmentation of KCs after Bacille-Calemette-Guerin vaccination largely increased hepatic CETP expres

4 The variable efficacy of Bacille Calmette Guerin (BCG) vaccination against tuberculosis has prompt

5 every year even though the bacille Calmette Guerin (BCG) vaccine has been available for more than 75

6 owth of Mycobacterium bovis bacille Calmette Guerin and Mycobacterium tuberculosis was impaired 7.3-

7 Bacille Calmette Guerin-vaccinated children were more likely to be PfHRP-

8 ad not been vaccinated with Bacille-Calmette Guerin (BCG).

9 binant Mycobacterium bovis bacillus Calmette Guerin (BCG) expressing the vector only (BCG-vector) res

10 d with Mycobacterium bovis bacillus Calmette Guerin (BCG) represents a potential strategy for prevent

11 mutant Mycobacterium bovis bacillus Calmette Guerin (BCG) strains to identify genes that decrease maj

12 culosis (TB) infection and bacillus Calmette Guerin (BCG) vaccination.

13 cine against tuberculosis, bacillus Calmette Guerin (BCG), has traditionally been viewed not to induc

14 The Bacillus Calmette - Guerin (BCG) vaccine provides a critical but limited def

15 ical agent in patients with bacille Calmette-Guerin (BCG) -refractory transitional cell carcinoma of

16 igote vaccine cocktail plus bacille Calmette-Guerin (BCG) adjuvant significantly reduced the incidenc

17 at are absent from M. bovis bacille Calmette-Guerin (BCG) and most environmental mycobacteria.

18 rial challenge model, using bacille Calmette-Guerin (BCG) as a surrogate for a Mycobacterium tubercul

19 Use of bacille Calmette-Guerin (BCG) as a surrogate for human Mycobacterium tube

20 Live attenuated Bacille Calmette-Guerin (BCG) bacillus is the only licensed vaccine for t

21 ycobacterium bovis known as bacille Calmette-Guerin (BCG) has been widely used as a vaccine for preve

22 on with Mycobacterium bovis bacille Calmette-Guerin (BCG) has variable efficacy in preventing tubercu

23 lates of TB disease risk in Bacille Calmette-Guerin (BCG) immunized infants from the MVA85A efficacy

24 ific to Mycobacterium bovis bacille Calmette-Guerin (BCG) in the lungs, and the IFN-gamma CD8 T cell

25 n PMCs were stimulated with bacille Calmette-Guerin (BCG) in vitro, they expressed ICAM-1 in a time-d

26 ium and Mycobacterium bovis Bacille Calmette-Guerin (BCG) in vitro.

27 tis and Mycobacterium bovis bacille Calmette-Guerin (BCG) in which a very high proportion of infected

28 during Mycobacterium bovis Bacille Calmette-Guerin (BCG) infection and a clear memory-type response

29 ding to Mycobacterium bovis bacille Calmette-Guerin (BCG) infection and disrupt granuloma formation,

30 diet on Mycobacterium bovis bacille Calmette-Guerin (BCG) infection.

31 e tuberculosis (TB) vaccine bacille Calmette-Guerin (BCG) is a live attenuated organism, but the muta

32 Bacille Calmette-Guerin (BCG) is an attenuated strain of Mycobacterium bo

33 dividuals with a history of Bacille Calmette-Guerin (BCG) vaccination after infancy or with repeated

34 tibody responses induced by bacille Calmette-Guerin (BCG) vaccination and active tuberculosis infecti

35 adermal Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccination as a surrogate for M. tuberculo

36 nmental mycobacteria and/or bacille Calmette-Guerin (BCG) vaccination compromise the estimates derive

37 Bacille Calmette-Guerin (BCG) vaccination has been suggested to have nons

38 Here we show that bacille Calmette-Guerin (BCG) vaccination in healthy volunteers led not o

39 Bacille Calmette-Guerin (BCG) vaccination induces a marked increase in th

40 Bacille Calmette-Guerin (BCG) vaccination may induce persistent and boost

41 the context of experimental bacille Calmette-Guerin (BCG) vaccination, Ag-specific T cell responses t

42 Bacille Calmette-Guerin (BCG) vaccination, known to induce partial protec

43 mately 100 million doses of bacille Calmette-Guerin (BCG) vaccine are given each year to protect agai

44 by the Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine are multifaceted and poorly underst

45 Because Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine can confer protection against fatal

46 es regarding the use of the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis vary greatly throu

47 therapeutic agents and the bacille Calmette-Guerin (BCG) vaccine have not significantly affected the

48 n mice infected with either bacille Calmette-Guerin (BCG) vaccine or virulent M. tuberculosis (77 and

49 During 1986-1989, a bacille Calmette-Guerin (BCG) vaccine trial was carried out in northern M

50 oma vaccine, Canvaxin, plus Bacille Calmette-Guerin (BCG) versus placebo plus BCG.

51 aques previously exposed to bacille Calmette-Guerin (BCG) were reinfected with BCG, were treated eith

52 previously established that bacille Calmette-Guerin (BCG), an attenuated form of Mycobacterium bovis,

53 Bacille Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovi

54 he cells were infected with bacille Calmette-Guerin (BCG), and intracellular mycobacterial traffickin

55 . tuberculosis and M. bovis Bacille Calmette-Guerin (BCG), using reverse transcription-polymerase cha

56 tis and Mycobacterium bovis bacille Calmette-Guerin (BCG), which respectively induce high and low aut

57 SIVmac)/Mycobacterium bovis bacille Calmette-Guerin (BCG)-coinfected macaque model.

58 cy virus (HIV)-infected and bacille Calmette-Guerin (BCG)-immunized adults with CD4 cell counts of >o

59 5A (M.85A), strongly boosts bacille Calmette-Guerin (BCG)-induced Ag 85A specific CD4(+) and CD8(+) T

60 Mycobacterium bovis strain bacille Calmette-Guerin (BCG)-induced granulomas using an immunocompetent

61 In Mycobacterium bovis Bacille Calmette-Guerin (BCG)-infected wild-type mice, there was a large

62 T cells when used alone in bacille Calmette-Guerin (BCG)-naive healthy volunteers.

63 odstream infection (BSI) in bacille Calmette-Guerin (BCG)-vaccinated children with human immunodefici

64 ovis-derived vaccine strain bacille Calmette-Guerin (BCG).

65 orm of Mycobacterium bovis, bacille Calmette-Guerin (BCG).

66 nuated tuberculosis vaccine bacille Calmette-Guerin (BCG).

67 ed with Mycobacterium bovis bacille Calmette-Guerin (BCG).

68 the vaccine strain M. bovis bacille Calmette-Guerin (BCG).

69 d against the mycobacterium bacille Calmette-Guerin (BCG).

70 2.3 weeks (IQR 1.4-4.6) for bacille Calmette-Guerin (BCG); 2.4 weeks (1.2-3.3) for diphtheria, tetanu

71 Intravesical bacille Calmette-Guerin (including a maintenance regimen) should be used

72 lves the use of recombinant bacille Calmette-Guerin (rBCG) overexpressing protective TB antigens.

73 against Mycobacterium bovis bacille Calmette-Guerin and virulent M. tuberculosis.

74 ontrast, the vaccine strain bacille Calmette-Guerin as well as RD-1 and ESAT-6 mutants of H37Rv faile

75 ted NO-dependent killing of bacille Calmette-Guerin by macrophages.

76 this article that although bacille Calmette-Guerin controlled M. tuberculosis growth for 7 wk of inf

77 o macrophages infected with bacille Calmette-Guerin expressing the green fluorescent protein, molecul

78 ive combination therapy for bacille Calmette-Guerin failures.

79 s a second-line therapy for bacille Calmette-Guerin failures.

80 e addition of interferon to bacille Calmette-Guerin has proven to be an effective combination therapy

81 cobacterium tuberculosis or bacille Calmette-Guerin have been shown to facilitate presentation of ova

82 Bacille Calmette-Guerin is the most effective therapy for carcinoma in si

83 erculosis vaccines to boost bacille Calmette-Guerin or for those who cannot be immunized with bacille

84 sure of Mycobacterium bovis Bacille Calmette-Guerin or Mycobacterium marinum to thiacetazone, a secon

85 tic granulomas triggered by Bacille Calmette-Guerin or Mycobacterium tuberculosis.

86 on with Mycobacterium bovis bacille Calmette-Guerin resulted in approximately 10-fold-higher bacteria

87 e intravesical therapy with bacille Calmette-Guerin should be considered for ongoing maintenance ther

88 sis and Mycobacterium bovis bacille Calmette-Guerin similarly home to established granulomas in mice.

89 illness, isoniazid use, and bacille Calmette-Guerin strain did not substantially affect vaccine effic

90 uberculous mycobacteria and bacille Calmette-Guerin vaccination may account for a proportion of test

91 Bacille Calmette-Guerin vaccination, tuberculosis prevalence in country o

92 ared with standard M. bovis bacille Calmette-Guerin vaccination.

93 city in those receiving the bacille Calmette-Guerin vaccine and poor sensitivity in individuals with

94 Research into the bacille Calmette-Guerin vaccine demonstrated the importance of comparativ

95 als of the effectiveness of bacille Calmette-Guerin vaccine in preventing active tuberculosis yielded

96 The bacille Calmette-Guerin vaccine provides very efficient protection in sta

97 The failure of the bacille Calmette-Guerin vaccine, synergy between AIDS and TB, and the eme

98 icacy of the currently used bacille Calmette-Guerin vaccine.

99 Failure to replace Bacille Calmette-Guerin vaccines with efficacious anti-tuberculosis (TB)

100 ion with M. tuberculosis or bacille Calmette-Guerin, or treatment with LPS or TNF-alpha.

101 sis and Mycobacterium bovis bacille Calmette-Guerin, release MVs when growing in both liquid culture

102 ting ones improved to treat bacille Calmette-Guerin-refractory superficial bladder cancer.

103 shown previously to induce bacille Calmette-Guerin-specific gammadelta T cells.

104 01, in a phase IIa trial of bacille Calmette-Guerin-vaccinated, HIV-uninfected, and Mycobacterium tub

105 dder cancer who have failed bacille Calmette-Guerin.

106 modified vaccine mixed with bacille Calmette-Guerin.

107 these 19 patients with live bacille Calmette-Guerin.

108 ho cannot be immunized with bacille Calmette-Guerin.

109 on with Mycobacterium bovis Bacille-Calmette-Guerin (BCG).

110 to M. tuberculosis from the Bacille-Calmette-Guerin vaccine strain, they currently lack the specifici

111 . tuberculosis and M. bovis Bacille-Calmette-Guerin.

112 n with Mycobacterium bovis bacillus Calmette-Guerin (BCG) administered subcutaneously.

113 d upon Mycobacterium bovis bacillus Calmette-Guerin (BCG) all interfere with the action of the tuberc

114 n with Mycobacterium bovis bacillus Calmette-Guerin (BCG) alone or as a BCG prime/Mtb72F-boost regime

115 y by endotoxin but also by bacillus Calmette-Guerin (BCG) and CD40 ligand and was associated with (an

116 anisms Mycobacterium bovis bacillus Calmette-Guerin (BCG) and M. tuberculosis.

117 l injection of heat-killed bacillus Calmette-Guerin (BCG) and subsequent activation using an intrader

118 onkeys were immunized with bacillus Calmette-Guerin (BCG) and then boosted with Mtb72F in AS02A, prot

119 this study, we found that bacillus Calmette-Guerin (BCG) and viable M. tuberculosis as well as M. tu

120 d with Mycobacterium bovis bacillus Calmette-Guerin (BCG) and were then challenged with virulent M. b

121 s a carrier and given with Bacillus Calmette-Guerin (BCG) as an adjuvant, elicited HMW-MAA-specific a

122 sed in Mycobacterium bovis bacillus Calmette-Guerin (BCG) but not when all seven phosphorylation site

123 ids of Mycobacterium bovis bacillus Calmette-Guerin (BCG) by coating the lipids onto 90-microm diamet

124 ion of Mycobacterium bovis bacillus Calmette-Guerin (BCG) continues to be a successful immunotherapy

125 rast, the vaccine M. bovis bacillus Calmette-Guerin (BCG) does not stimulate MMP-1 secretion from hum

126 unization with recombinant bacillus Calmette-Guerin (BCG) expressing RSV nucleoprotein prevented beha

127 a since avirulent M. bovis bacillus Calmette-Guerin (BCG) fails to trigger significant expression of

128 Although maintenance bacillus Calmette-Guerin (BCG) for at least 1 year has been recommended, s

129 ents who fail intravesical bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder cancer (NMIB

130 though Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been accepted as the most effective age

131 Vaccination with Bacillus Calmette-Guerin (BCG) has been shown to reduce the severity and p

132 Bacillus Calmette-Guerin (BCG) has been used for vaccination against tuber

133 Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been used to treat bladder cancer for a

134 ation of patients for whom bacillus Calmette-Guerin (BCG) has failed, the type of failure (BCG unresp

135 routinely vaccinated with bacillus Calmette-Guerin (BCG) in areas of the world where worm infections

136 before revaccination with bacillus Calmette-Guerin (BCG) in healthy, tuberculin skin test-positive (

137 wth of Mycobacterium bovis bacillus Calmette-Guerin (BCG) in human macrophages.

138 Mycobacterium bovis strain bacillus Calmette-Guerin (BCG) in mice.

139 is and Mycobacterium bovis bacillus Calmette-Guerin (BCG) induce potent expansions of human memory Vg

140 s of CD4(+) T cells during bacillus Calmette-Guerin (BCG) infection of mice.

141 Mycobacterium bovis strain bacillus Calmette-Guerin (BCG) infection we studied the extent of T cell h

142 lowing Mycobacterium bovis bacillus Calmette-Guerin (BCG) infection.

143 murine Mycobacterium bovis bacillus Calmette-Guerin (BCG) infection.

144 Although Bacillus Calmette-Guerin (BCG) intravesical therapy is a standard treatmen

145 Mycobacterium bovis bacillus Calmette-Guerin (BCG) is the only vaccine approved for prevention

146 d with Mycobacterium bovis bacillus Calmette-Guerin (BCG) nor tuberculin skin test (TST) positive (gr

147 d with Mycobacterium bovis bacillus Calmette-Guerin (BCG) or Mycobacterium avium.

148 e dose (1 x 10(5) CFUs) of bacillus Calmette-Guerin (BCG) or Mycobacterium vaccae via nasal or perito

149 Bacillus Calmette-Guerin (BCG) osteitis was more common in Finland than el

150 tuberculosis and M. bovis bacillus Calmette-Guerin (BCG) Pasteur in vivo and in vitro.

151 um bovis Ravenel, M. bovis bacillus Calmette-Guerin (BCG) Pasteur, and M. bovis BCG Montreal were com

152 rol of Mycobacterium bovis bacillus Calmette-Guerin (BCG) pleural infection in a murine model.

153 therapy with intravesical bacillus Calmette-Guerin (BCG) plus IFN-alpha for superficial bladder canc

154 h live Mycobacterium bovis Bacillus Calmette-Guerin (BCG) produced large amounts of CXCL1 and CXCL2,

155 n with Mycobacterium bovis bacillus Calmette-Guerin (BCG) remains the only prophylactic vaccine again

156 Bacillus Calmette-Guerin (BCG) seems to have beneficial nonspecific effect

157 The bacillus Calmette-Guerin (BCG) strain of Mycobacterium bovis is used in ma

158 refractory to intravesical bacillus Calmette-Guerin (BCG) therapy and refusing a cystectomy were cons

159 using Mycobacterium bovis bacillus Calmette-Guerin (BCG) to prime and modified vaccinia virus Ankara

160 ure of Mycobacterium bovis bacillus Calmette-Guerin (BCG) to protect against disease, new vaccines ag

161 n apoptotic regulation and bacillus Calmette-Guerin (BCG) treatment in murine peritoneal exudate macr

162 ) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse

163 according to intravesical Bacillus Calmette-Guerin (BCG) treatment status: no BCG, induction BCG (iB

164 Mycobacterium bovis Bacillus Calmette-Guerin (BCG) use in the treatment of bladder cancer was

165 IGRAs was associated with bacillus Calmette-Guerin (BCG) vaccination (odds ratio: 25.1 [95% confiden

166 ed the association between bacillus Calmette-Guerin (BCG) vaccination and childhood asthma in a birth

167 producing IFN-gamma during bacillus Calmette-Guerin (BCG) vaccination and subsequent M. tuberculosis

168 rventions, such as IPT and bacillus Calmette-Guerin (BCG) vaccination for preventing TB disease among

169 Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination is efficacious for newborns or

170 tudies have suggested that Bacillus Calmette-Guerin (BCG) vaccination may reduce the risk of allergic

171 ate analyses examined age, bacillus Calmette-Guerin (BCG) vaccination status, and sex as predictor va

172 ced by Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination to protect against mycobacteria

173 after primary or secondary bacillus Calmette-Guerin (BCG) vaccination were assessed for Ab responses

174 culosis (strain H37Rv) and bacillus Calmette-Guerin (BCG) vaccine inhibit phagosome maturation in mac

175 Bacillus Calmette-Guerin (BCG) vaccine is the most widely administered vac

176 Bacillus Calmette-Guerin (BCG) vaccine is widely used for the prevention o

177 h an autologous tumor cell-bacillus Calmette-Guerin (BCG) vaccine was conducted to determine whether

178 inations studied comprised Bacillus Calmette-Guerin (BCG) vaccine, Triple vaccine, Hepatitis B vaccin

179 proved Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine-induced protection was lost in the

180 effective than the present bacillus Calmette-Guerin (BCG) vaccine.

181 rapy instillation with the bacillus Calmette-Guerin (BCG) vaccine.

182 denitis caused by the live Bacillus Calmette-Guerin (BCG) vaccine.

183 ad previously received the bacillus Calmette-Guerin (BCG) vaccine; among this vaccinated group, the r

184 Although Bacillus Calmette-Guerin (BCG) vaccines against tuberculosis have been ava

185 ion, recombinant clones of bacillus Calmette-Guerin (BCG) were engineered to express the natural anta

186 ), and Mycobacterium bovis bacillus Calmette-Guerin (BCG) were studied for their ability to be activa

187 strain Mycobacterium bovis bacillus Calmette-Guerin (BCG), and it is hypothesized that these proteins

188 ates, based on recombinant bacillus Calmette-Guerin (BCG), attenuated Mycobacterium tuberculosis, or

189 model of vaccination with bacillus Calmette-Guerin (BCG), followed by challenge with virulent M. tub

190 he only vaccine available, Bacillus Calmette-Guerin (BCG), has been used since its inception in 1921.

191 ccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), is contraindicated for immunocompromised i

192 the current live vaccine, bacillus Calmette-Guerin (BCG), is desperately needed.

193 ccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), is largely ineffective, and ways to enhanc

194 ages infected with M bovis Bacillus Calmette-Guerin (BCG), M phlei, M avium 2151-rough, and M tubercu

195 n with Mycobacterium bovis bacillus Calmette-Guerin (BCG), peaking by days 14-21 posttreatment.

196 Bacillus Calmette-Guerin (BCG), the antituberculosis vaccine, localizes wi

197 Bacillus Calmette-Guerin (BCG), the tuberculosis vaccine, is an attenuated

198 log in Mycobacterium bovis Bacillus Calmette-Guerin (BCG), we show for the first time that acetylatio

199 ity is Mycobacterium bovis bacillus Calmette-Guerin (BCG), which has been used in newborns for many d

200 ed descendant of M. bovis, bacillus Calmette-Guerin (BCG), widely used as a vaccine against human tub

201 vel breast cancer vaccine, Bacillus Calmette-Guerin (BCG)-hIL2MUC1, that consists of BCG and expresse

202 culosis susceptibility and bacillus Calmette-Guerin (BCG)-induced immunity are mostly unknown.

203 e that Mycobacterium bovis bacillus Calmette-Guerin (BCG)-mediated TLR2 signaling-induced iNOS/NO exp

204 85A, Ag85B, and TB10.4, in bacillus Calmette-Guerin (BCG)-primed or unprimed rhesus macaques.

205 blood mononuclear cells of bacillus Calmette-Guerin (BCG)-vaccinated individuals with live Mycobacter

206 gainst Mycobacterium bovis bacillus Calmette-Guerin (BCG).

207 ma and Mycobacterium bovis Bacillus Calmette-Guerin (BCG).

208 nuated Mycobacterium bovis bacillus Calmette-Guerin (BCG).

209 n with Mycobacterium bovis bacillus Calmette-Guerin (BCG).

210 s) and Mycobacterium bovis Bacillus Calmette-Guerin (BCG).

211 ses to Mycobacterium bovis bacillus Calmette-Guerin (BCG).

212 e to stimulation with live bacillus Calmette-Guerin (BCG; LOD score, 3.81; P = 1.40 x 10(-5)).

213 killed Mycobacterium bovis bacillus Calmette-Guerin (HK-BCG) i.p. did not release PGE(2).

214 ts the use of intravesical Bacillus Calmette-Guerin (including a maintenance regimen) for those at hi

215 rt the use of intravesical bacillus Calmette-Guerin (including a maintenance regimen) for those at hi

216 ty of Danish patients were bacillus Calmette-Guerin (Mycobacterium bovis BCG) vaccinated (CD, 77.5%;

217 th the attenuated M. bovis bacillus Calmette-Guerin [BCG]), and Mycobacterium microti; increasingly r

218 cell responses induced by bacillus Calmette-Guerin and a recombinant subunit protein vaccine to hepa

219 Immunomodulators such as Bacillus Calmette-Guerin and interferon are clinically active in transitio

220 eport, Mycobacterium bovis bacillus Calmette-Guerin and M. tuberculosis H37Ra were used as models of

221 n with Mycobacterium bovis bacillus Calmette-Guerin and Mycobacterium tuberculosis.

222 ccine, Mycobacterium bovis-bacillus Calmette-Guerin as well as in mice infected i.v. with M. tubercul

223 with the Moreau strain of bacillus Calmette-Guerin but not after infection with other strains.

224 erium tuberculosis and the bacillus Calmette-Guerin can be tracked directly in the lungs of living mi

225 n with Mycobacterium bovis bacillus Calmette-Guerin compared with control mice after infection with M

226 oss processing of M. bovis bacillus Calmette-Guerin expressing OVA could be circumvented by pretreati

227 oss processing of M. bovis bacillus Calmette-Guerin expressing OVA, bypassing the inhibition of induc

228 ion by Mycobacterium bovis bacillus Calmette-Guerin failed to induce IRF-1 expression and had no effe

229 sis or Mycobacterium bovis bacillus Calmette-Guerin failed to induce TLR-dependent activation.

230 rus or Mycobacterium bovis bacillus Calmette-Guerin had no effect.

231 tuberculosis comparable to bacillus Calmette-Guerin immunization.

232 n with Mycobacterium bovis bacillus Calmette-Guerin in mice.

233 igands or bacteria such as bacillus Calmette-Guerin increases antitumor immune responses and delays t

234 nuated Mycobacterium bovis bacillus Calmette-Guerin induces less PPARgamma and preferentially uses th

235 lowing Mycobacterium bovis bacillus Calmette-Guerin infection and costimulation with IFN-gamma, we ob

236 resented with disseminated Bacillus Calmette-Guerin infection and oligoclonal T cells with no naive m

237 tuberculosis and M. bovis bacillus Calmette-Guerin infection down-regulated the expression of CIITA/

238 ng Th1 immune responses to Bacillus Calmette-Guerin infection in vivo.

239 uced in macrophages during bacillus Calmette-Guerin infection.

240 bacterium tuberculosis and bacillus Calmette-Guerin infections of macaques induced expression of vari

241 nse to Mycobacterium bovis bacillus Calmette-Guerin infections.

242 ogenic Mycobacterium bovis bacillus Calmette-Guerin intracellular survival, downregulated antimicrobi

243 y attenuating mechanism of bacillus Calmette-Guerin is the loss of cytolytic activity mediated by sec

244 Evidence suggests that bacillus Calmette-Guerin is the most effective intravesical therapy for th

245 ore effective vaccine than bacillus Calmette-Guerin is urgently needed.

246 also lowered intracellular Bacillus Calmette-Guerin levels in mammary epithelial cancer MCF-7 cells.

247 lternatives to traditional Bacillus Calmette-Guerin needles and syringes for the administration of fI

248 wth of Mycobacterium bovis bacillus Calmette-Guerin on minimal but not rich medium.

249 accine Mycobacterium bovis bacillus Calmette-Guerin or the adoptive transfer of mycobacteria-activate

250 viable Mycobacterium bovis bacillus Calmette-Guerin or TLR ligands.

251 binant Mycobacterium bovis bacillus Calmette-Guerin overexpressing the 30-kDa antigen, C3HeB/FeJ mice

252 at M. marinum and M. bovis bacillus Calmette-Guerin produce a type of spore known as an endospore, wh

253 vealed that currently used bacillus Calmette-Guerin strains vary in their ability to affect correlate

254 er (NMIBC) recurrent after bacillus Calmette-Guerin therapy is complex and further complicated by hig

255 e with Mycobacterium bovis bacillus Calmette-Guerin to augment host immunity before infection with vi

256 ther dietary approaches, a Bacillus Calmette-Guerin trial in 1976, molecular-targeted agents, and age

257 While bacillus Calmette-Guerin vaccination plays an important role in reducing t

258 f index cases, the age and bacillus Calmette-Guerin vaccination status of contacts, and study design

259 ced by Mycobacterium bovis bacillus Calmette-Guerin vaccination.

260 ble to those achieved with bacillus Calmette-Guerin vaccination.

261 lacebo together with their Bacillus Calmette-Guerin vaccination.

262 rsons who had received the Bacillus Calmette-Guerin vaccine in households with and without a microbio

263 ion of Mycobacterium bovis bacillus Calmette-Guerin vaccine in humans.

264 of mice to the attenuated bacillus Calmette-Guerin vaccine strain.

265 stimulation with live BCG (Bacillus Calmette-Guerin), and a second locus on chromosome region 3q affe

266 vium, Mycobacterium bovis (bacillus Calmette-Guerin), and Mycobacterium tuberculosis (strain H37Rv),

267 H37Ra, Mycobacterium bovis bacillus Calmette-Guerin, and M. kansasii) induced significantly more AMph

268 niae, Helicobacter pylori, bacillus Calmette-Guerin, and Mycobacterium tuberculosis) in a murine mode

269 protection at the level of bacillus Calmette-Guerin, and the fusion protein exhibited high predicted

270 red the childhood measles, bacillus Calmette-Guerin, diphtheria-pertussis-tetanus, polio, and materna

271 terium Mycobacterium bovis bacillus Calmette-Guerin, macrophages recovered from the peritoneal cavity

272 79c in Mycobacterium bovis bacillus Calmette-Guerin, plays an important role in mycobacterial surviva

273 Mycobacterium bovis bacillus Calmette-Guerin, the only vaccine available against tuberculosis

274 rcinoma in situ, nonuse of bacillus Calmette-Guerin, tumor size > 3 cm, and older age; HRs for progre

275 teria Escherichia coli and bacillus Calmette-Guerin, which increased other DC subsets.

276 Vegf-c is up-regulated in Bacillus Calmette-Guerin- and Mycobacterium tuberculosis-induced granuloma

277 tiation of Th17 cells from bacillus Calmette-Guerin-challenged (BCG-challenged) lung CD4+ T cells.

278 M. tuberculosis var. bovis Bacillus Calmette-Guerin-induced p38 MAPK activity caused a marked increas

279 Bacillus Calmette-Guerin-induced production of the proinflammatory cytokin

280 Granulomas of bacillus Calmette-Guerin-infected humanized mice administered with a TNF-n

281 d in livers and lungs from bacillus Calmette-Guerin-infected humanized mice but not in nonhumanized i

282 m M. tuberculosis- but not bacillus Calmette-Guerin-infected humanized mice.

283 Mycobacterium bovis bacillus Calmette-Guerin-infected IL-10(-/-) mice had significantly lower

284 from the serum of M. bovis bacillus Calmette-Guerin-infected mice could also stimulate macrophage pro

285 with Mtb-infected, but not bacillus Calmette-Guerin-infected, targets.

286 M. bovis bacillus Calmette-Guerin-primed sanroque T cells transferred into Rag1(-/-

287 ward developing agents for bacillus Calmette-Guerin-refractory superficial bladder cancer continue, h

288 development of agents for bacillus Calmette-Guerin-refractory superficial bladder cancer.

289 ent cystoprostatectomy for bacillus Calmette-Guerin-refractory, high-grade noninvasive UC.

290 Furthermore, bacillus Calmette-Guerin-vaccinated IFN-gamma-deficient mice exhibited sig

291 ion by CD4(+) T cells from bacillus Calmette-Guerin-vaccinated mice and show that high-quality microa

292 strain Mycobacterium bovis bacillus Calmette-Guerin.

293 activity against M. bovis bacillus Calmette-Guerin.

294 s, and Mycobacterium bovis bacillus Calmette-Guerin.

295 a protein not expressed by bacillus Calmette-Guerin.

296 parable to that induced by bacillus Calmette-Guerin.

297 s, and Mycobacterium bovis bacillus Calmette-Guerin.

298 strain Mycobacterium bovis bacillus Calmette-Guerin.

299 autologous tumor cells admixed with Calmette-Guerin bacillus.

300 In this issue of Neuron, Guerin et al. provide novel evidence that distinct parie